BRPI0513938A - composição farmacêutica contendo drospirenona e etinilestradiol - Google Patents

composição farmacêutica contendo drospirenona e etinilestradiol

Info

Publication number
BRPI0513938A
BRPI0513938A BRPI0513938-4A BRPI0513938A BRPI0513938A BR PI0513938 A BRPI0513938 A BR PI0513938A BR PI0513938 A BRPI0513938 A BR PI0513938A BR PI0513938 A BRPI0513938 A BR PI0513938A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition containing
ethinyl estradiol
containing drospirenone
ethinylestradiol
Prior art date
Application number
BRPI0513938-4A
Other languages
English (en)
Inventor
Carlos Ariel Sandrone
Jose Mario Sakson
Maria Del Carmen C Basaistegui
Jose Daniel Larrosa Pomi
Original Assignee
Liconsa Laboratorios Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513938(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liconsa Laboratorios Sa filed Critical Liconsa Laboratorios Sa
Publication of BRPI0513938A publication Critical patent/BRPI0513938A/pt
Publication of BRPI0513938B1 publication Critical patent/BRPI0513938B1/pt
Publication of BRPI0513938B8 publication Critical patent/BRPI0513938B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçãO FARMACêUTICA CONTENDO DROSPIRENONA E ETINILESTRADIOL Trata-se a presente invenção de uma composição farmacêutica contendo Drospirenona e Etinilestradiol, com uma taxa de dissolução melhorada, bem como de um método de preparação de uma formulação farmacêutica contendo Drospirenona e Etinilestradiol, para que seu perfil de dissolução seja melhorado. A dita formulação farmacêutica pode ser utilizada para produzir um efeito anovulatório, quando administrada corretamente, em seres humanos.
BRPI0513938A 2004-08-09 2005-08-02 composição farmacêutica contendo drospirenona e etinilestradiol BRPI0513938B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103837A EP1625849A1 (en) 2004-08-09 2004-08-09 Pharmaceutical composition comprising drospirenone and ethynylestradiol
PCT/EP2005/053759 WO2006015956A1 (en) 2004-08-09 2005-08-02 Pharmaceutical composition comprising drospirenone and ethynylestradiol

Publications (3)

Publication Number Publication Date
BRPI0513938A true BRPI0513938A (pt) 2008-05-20
BRPI0513938B1 BRPI0513938B1 (pt) 2018-09-25
BRPI0513938B8 BRPI0513938B8 (pt) 2021-05-25

Family

ID=34929434

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513938A BRPI0513938B8 (pt) 2004-08-09 2005-08-02 composição farmacêutica contendo drospirenona e etinilestradiol

Country Status (19)

Country Link
US (1) US20090227546A1 (pt)
EP (2) EP1625849A1 (pt)
JP (1) JP2008509195A (pt)
KR (1) KR20070045247A (pt)
CN (1) CN101022811B (pt)
AR (1) AR045576A1 (pt)
AT (1) ATE464053T1 (pt)
AU (1) AU2005271206B2 (pt)
BR (1) BRPI0513938B8 (pt)
CA (1) CA2574997A1 (pt)
DE (1) DE602005020694D1 (pt)
ES (1) ES2344356T3 (pt)
IL (1) IL180899A0 (pt)
MA (1) MA28844B1 (pt)
NO (1) NO20071297L (pt)
RU (1) RU2007108666A (pt)
UA (1) UA87513C2 (pt)
WO (1) WO2006015956A1 (pt)
ZA (1) ZA200702038B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5649305B2 (ja) * 2006-12-20 2015-01-07 テバ ウィメンズ ヘルス インコーポレイテッド プロゲスチンを含む口腔内崩壊性固体剤形ならびにその製造方法および使用方法
HUP0700826A3 (en) * 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US20100256194A1 (en) * 2009-04-01 2010-10-07 Bial - Portela & Ca, S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
ES2730678T3 (es) 2009-04-01 2019-11-12 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas
US10849857B2 (en) * 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) * 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CN102274235B (zh) * 2011-06-27 2013-03-13 潍坊中狮制药有限公司 一种新的避孕药物组合及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
SK287634B6 (sk) * 1999-08-31 2011-04-05 Bayer Schering Pharma Aktiengesellschaft Farmaceutická kompozícia obsahujúca drospirenón a etinylestradiol a farmaceutický prípravok
BR0014159A (pt) * 1999-08-31 2002-05-07 Schering Ag Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional
CA2431521E (en) * 2000-12-14 2013-04-16 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products and methods for preparing them
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes

Also Published As

Publication number Publication date
HK1109579A1 (en) 2008-06-13
BRPI0513938B1 (pt) 2018-09-25
CA2574997A1 (en) 2006-02-16
ES2344356T3 (es) 2010-08-25
IL180899A0 (en) 2007-07-04
WO2006015956A1 (en) 2006-02-16
EP1848441A1 (en) 2007-10-31
JP2008509195A (ja) 2008-03-27
ATE464053T1 (de) 2010-04-15
KR20070045247A (ko) 2007-05-02
MA28844B1 (fr) 2007-09-03
ZA200702038B (en) 2008-08-27
NO20071297L (no) 2007-05-02
BRPI0513938B8 (pt) 2021-05-25
EP1848441B1 (en) 2010-04-14
AR045576A1 (es) 2005-11-02
RU2007108666A (ru) 2008-09-20
AU2005271206A1 (en) 2006-02-16
CN101022811A (zh) 2007-08-22
CN101022811B (zh) 2010-09-15
AU2005271206B2 (en) 2009-11-26
DE602005020694D1 (de) 2010-05-27
UA87513C2 (ru) 2009-07-27
EP1625849A1 (en) 2006-02-15
US20090227546A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
DOP2014000260A (es) Compuestos d-aminoácidos para enfermedad hepática
AR045352A1 (es) Forma de dosificacion a prueba de abuso
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
DOP2007000102A (es) Arilimidazolonas y ariltriazolona sustituidas asi como su uso
BRPI0513938A (pt) composição farmacêutica contendo drospirenona e etinilestradiol
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
EA201001285A1 (ru) Применение 25-oh d3 для воздействия на физиологию мышц человека
BRPI0912842A8 (pt) composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
GT200500235A (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos
BRPI0908541B8 (pt) uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
EP2515912A4 (en) Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos
NO20091628L (no) Kombinasjonsmedikament
BR112013002945A2 (pt) composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: PAGAR RESTAURACAO.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF